INmune Bio Q2 net loss narrows on lower impairment charges - INMB News | RalliesINmune Bio Q2 net loss narrows on lower impairment charges
I
INMB• Result drivers
- R&D tax rebate - The company said recognition of an Australian R&D tax rebate reduced research and development expenses in Q2.
- No impairment charges - The company said the prior-year period included a $16.5 million impairment charge that did not recur in Q2 2026.
Quarterly results
- INmune Bio said its Q2 net loss narrowed sharply from the prior year.
- The company reported no revenue for the quarter.
- Q2 results benefited from an Australian R&D tax rebate and lower impairment charges.
Outlook and pipeline
- The company plans a UK MAA submission for Ebstrocel by the end of Q3 or early Q4 2026.
- INmune Bio expects EU EMA and US FDA submissions for Ebstrocel in Q1 2027.
- The company expects XPro Phase 2b/3 protocol submission to the FDA in Q4 2026.
Key figures and analyst view
| Metric | Actual |
|---|
| Q2 net loss | $1.27 million |
| Q2 loss per basic share | $0.05 |
| Q2 operating expenses | $1.48 million |
- The current average analyst rating on the shares is "buy", with 4 "strong buy" or "buy" ratings, no "hold" and no "sell" or "strong sell".
- The average consensus recommendation for the biotechnology and medical research peer group is "buy".
- Wall Street's median 12-month price target for INmune Bio Inc is $7.50, about 294.7% above its August 5 closing price of $1.90.
WLDN
•
